How Safe Is GlaxoSmithKline plc’s 6% Dividend Yield?

How safe is GlaxoSmithKline plc’s (LON: GSK) dividend?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) currently supports one of the largest dividend yields in the FTSE 100.

At present, the company’s shares yield just under 6%, around double the market average, making them extremely attractive in the current interest rate environment. 

However, it is often the case that a higher-than-average dividend yield like Glaxo’s reflects the market’s belief that the company is sick and will have trouble maintaining its dividend payout. 

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

That said, Glaxo’s management has stated that the group’s dividend payout will remain at 80p per share for the next three years. This indicates that the company will yield 5.9% for the next three years based on the current price. 

But how realistic is management’s outlook? It’s not uncommon for companies to guarantee their dividend payouts, only to backtrack and slash the payout a few months later.

So, will Glaxo’s management stay true to their word?

Crunching numbers

According to my figures, it looks as if Glaxo will be able to maintain a payout of 80p per share for the next few years. 

Last year the company generated £5.2bn in cash from operations. Meanwhile, the group’s capital spending totalled £1.7bn, giving a free cash flow of £3.5bn. During the past five years, on average Glaxo has reported a free cash flow of approximately £4.4bn. 

Free cash flow gives a much clearer view of a company’s ability to maintain its dividend payout. Indeed, without cash, it’s tough to invest without borrowing, pay dividends and reduce debt. Earnings can often be clouded by accounting gimmicks, but it’s tougher to fake cash flow. 

Funding the payout

With around 4.9bn shares in issue, a dividend of 80p per share per annum will cost Glaxo around £3.9bn per annum to maintain. According to last year’s figures, Glaxo’s dividend payout of 80p per share cost the company a total of £3.8bn. 

Unfortunately, this figure of £3.8bn is only just covered by Glaxo’s free cash flow based on the five-year average. With this being the case, Glaxo doesn’t have much room for manoeuvre and if things don’t go to plan the company could struggle to make ends meet. 

Still, these figures are based on historic numbers and don’t take into account the initiatives Glaxo has in place to improve profit margins. 

Specifically, the group is on track to achieve annualised cost savings of £3bn by the end of 2017. Also, Glaxo is set to receive £3bn from its recent asset swap deal with Novartis. As part of this deal, a further £1bn will be returned to investors via a special dividend. 

Moreover, Glaxo’s management believes that the company’s earnings will expand at a compound annual rate in the mid-to-high single digits from 2016 onwards, further boosting group cash flow. 

Looks safe

All in all, Glaxo’s lofty dividend yield seems to be safe for the time being. The dividend is covered by free cash flow at present and cost-saving initiatives, coupled with earnings growth should only help improve dividend cover.

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won’t want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we’re giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 reasons Tesla stock may be a long-term bargain

This writer is keen to buy Tesla stock at the right price. He doesn't think it's there yet -- but…

Read more »

Investing Articles

Nvidia stock is a lot cheaper than before – or is it?

Nvidia stock has been caught in the whirlwind of market volatility. This writer has been waiting to buy, so might…

Read more »

Top Stocks

3 FTSE stocks Fools are eyeing up for choppy markets

A selection of companies listed on the UK stock market on the watchlists of four Foolish investors.

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

A £10,000 investment in Rolls-Royce shares last week is now worth this…

Harvey Jones says Rolls-Royce shares couldn't escape the volatility of recent weeks, but wonders if the recent dip is a…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Prediction: in 2 years these S&P 500 stocks will be much higher than they are today

These two S&P 500 stocks have been beaten down in recent weeks. But Edward Sheldon expects them to move much…

Read more »

Investing Articles

10% yields! Why a volatile stock market is great news for passive income investors

The recent stock market volatility has given passive income investors the chance to earn double-digit returns. But they still need…

Read more »

Close up of manual worker's equipment at construction site without people.
Investing Articles

Down 65% from its highs, this FTSE 250 stock is one to consider buying low

Shares in a strong FTSE 250 company going through a cyclical downturn have caught Stephen Wright’s attention as a potential…

Read more »

Investing Articles

£20,000 invested in a Stocks and Shares ISA 5 years ago is now worth…

Stocks and Shares ISA investors have reaped enormous returns since the pandemic, but how much money have they actually made?…

Read more »